Revenue Performance - For the six months ended June 30, 2023, the company achieved total revenue of RMB 492.8 million, a decrease of RMB 166.7 million or 25.3% compared to RMB 659.5 million in the same period of 2022[3]. - COVID-19 related testing revenue was approximately RMB 7.9 million, down 96.3% year-on-year, while non-COVID-19 related testing revenue was RMB 484.8 million, showing a recovery growth of about 9.2%[3]. - Total revenue for the six months ended June 30, 2023, was RMB 492.76 million, a decrease of 25.3% compared to RMB 659.48 million for the same period in 2022[65]. - Revenue from clinical testing services decreased to RMB 486,207 thousand, down 26.0% from RMB 654,799 thousand for the same period in 2022[122]. - Total revenue from customer contracts was RMB 492,760 thousand, a decline of 25.3% compared to RMB 659,482 thousand in the prior year[122]. Profitability and Expenses - The company's gross profit for the period was RMB 243.9 million, a decrease of 18.3% year-on-year, but the gross margin improved from 45.3% to 49.5% due to an increase in non-COVID-19 testing revenue[3]. - For the six months ended June 30, 2023, the company's profit was RMB 43.5 million, reflecting a significant decrease due to lower overall profit compared to the same period last year[32]. - The company reported a profit before tax of RMB 46.70 million, down 35.8% from RMB 72.73 million in the previous year[65]. - The net profit for the period was RMB 43.49 million, a decrease of 31.2% compared to RMB 63.23 million for the same period in 2022[65]. - The company's income tax expense for the same period decreased by 66.2% to RMB 3.2 million, primarily due to a decline in total profit[31]. Cash Flow and Financial Position - The company reported a net cash flow used in operating activities of RMB 7.6 million for the six months ended June 30, 2023[21]. - Cash and cash equivalents increased by 77.1% from RMB 680.4 million as of December 31, 2022, to RMB 1,204.7 million as of June 30, 2023[23]. - The group’s cash and cash equivalents increased significantly to RMB 1,204,663 thousand, compared to RMB 680,359 thousand as of December 31, 2022[78]. - As of June 30, 2023, total current liabilities amounted to RMB 800.53 million, a decrease from RMB 861.55 million at the end of 2022[71]. - The total assets less current liabilities stood at RMB 2,972.64 million, an increase from RMB 2,863.79 million at the end of 2022[71]. Research and Development - Research and development costs for the six months ended June 30, 2023, were RMB 52.8 million, an increase of 17.9% year-on-year, attributed to the addition of 102 new testing items[29]. - Research and development expenses increased to RMB 52.78 million from RMB 44.76 million, representing a year-over-year increase of 17.5%[65]. - The R&D project testing services revenue rose to RMB 6,553 thousand, an increase of 39.8% from RMB 4,683 thousand in the same period last year[122]. Administrative and Other Expenses - Administrative expenses increased by 26.8% year-on-year to RMB 49.3 million, primarily due to rising administrative and management costs associated with business expansion[28]. - The group’s administrative expenses were RMB 38,829 thousand, indicating a rise in operational costs[116]. - Sales and marketing expenses remained stable at RMB 159.6 million compared to the same period last year[47]. Future Outlook and Plans - The company plans to leverage cash reserves for better business empowerment and to seize potential acquisition opportunities in the industry[9]. - The company expects higher quality development in the second half of 2023, driven by market expansion and the promotion of new specialized services and testing items[16]. - The company plans to allocate 15% of the net proceeds from the global offering, approximately RMB 308 million, to expand its hematology testing business[63]. - The company has set a target to utilize RMB 205.4 million (10% of proceeds) for the sales and marketing expansion of genetic and rare disease testing by June 30, 2025[63]. Shareholder Returns and Equity - No interim dividend was declared for the six months ended June 30, 2023[42]. - The company repurchased a total of 2,395,000 shares at a total cost of approximately RMB 4,828,000 during the first half of 2023[198]. - The company issued 957,621,184 shares as of June 30, 2023, down from 961,501,284 shares at the end of 2022[194]. Taxation and Compliance - The total tax expense for the six months ended June 30, 2023, was RMB 3,212,000, down from RMB 9,502,000 for the same period in 2022, representing a decrease of approximately 66.2%[176]. - The company has maintained a 15% preferential corporate income tax rate for its high-tech enterprises, valid until 2025[175]. - The group has subsidiaries in regions with preferential tax rates, including a 15% corporate income tax rate for high-tech enterprises[145][147]. Credit Risk and Receivables - The company has implemented strict controls over outstanding receivables to minimize credit risk, with regular reviews by senior management[162]. - The expected credit loss provision for trade receivables increased to RMB 65,410,000 from RMB 63,390,000, indicating a rise of about 3.2%[155]. - The company aims to strictly control overdue receivables to minimize credit risk, with senior management regularly reviewing overdue balances[182].

公司網站 www.kindstar.com.cn 股份代號 9960 簡明綜合全面收益表 附註： 9 康聖環球基因技術有限公司 2022 年年度報告 尊敬的各位股東： 本人謹代表董事會欣然提呈本集團截至2022年12月31日止年度的年度報告。截至2022年12月31日止的年度對於本集 團而言是富有挑戰的一年。這一年，我們取得了一定的成績，我們的收入實現人民幣1,386.6百萬元，同比增長49%。 這一年，我們也遭受到了上市以來最大的衝擊，受疫情影響，我們的核心專科特檢業務增長放緩。 2023年是新冠開放後恢復的第一年，中國專科特檢行業與中國經濟可能還會遇到一些波折，但是我們仍然有信心去面 對，我們相信最差的時候已經過去。展望未來三年，我們預計明後年公司將實現更快速的成長，我們對未來充滿信心， 對專科特檢各個領域保持樂觀。 長夜終去，黎明降至，在2023年新的一年裡，全體康聖人將保持努力拚搏的作風，用實際行動踐行「病人利益至上，醫 生需求第一」的宗旨，積極推進中國精準診斷事業的發展，用優異的業績回饋各位股東。 黃士昂 業績回顧及展望 專科特檢業務 業績回顧及展望 • 遺傳病及罕見病相關檢測 • 眼科相關檢測 2 ...

21. 業務合併 於2021年12月31日，本集團持有武漢海希30%股權。於2021年11月，本集團訂立了股權 轉讓協議（「日期為2021年11月30日的股權轉讓協議」），以向黃士昂先生及一名個別股東 進一步收購武漢海希21.77%的股權，總代價為人民幣10,657,900元。本集團亦與武漢海希 訂立增資協議（「日期為2021年11月30日的增資協議」，連同日期為2021年11月30日的股 權轉讓協議，統稱「日期為2021年11月30日的協議」），據此，本集團同意以現金方式向武 漢海希出資人民幣15,000,000元。前述收購及資本注資的交割條件包括武漢海希達到2021 年的若干銷售╱淨利潤目標及獲得本公司股東批准等。 隨著武漢海希實現銷售╱淨利潤目標，日期為2021年11月30日的協議項下的交割條件已 達成。收購於2022年1月21日完成，而本公司此時已獲得武漢海希從事經營及金融活動的 控制權，並已獲得本公司股東的批准。於2022年1月，已向黃士昂先生及一名個別股東支 付股權轉讓代價人民幣10,657,900元，並向武漢海希注資人民幣15,000,000元。於股權轉 讓及注資完成後，武漢海希由本集團持有51 ...

| --- | --- | --- | |------------------------------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 康圣环球 | | | | Kindstar Global Kindstar Globalgene Technology, Inc. 康 聖 環 球 基 因 技 術 有 限 公 司 | | 209 | | ( 於開曼群島註冊成立的有限公司 ) | | | | 股份代號 : 9960 | | | 目錄 2 釋義 5 公司資料 7 業務回顧及展望 15 管理層討論及分析 28 其他資料 40 獨立審閱報告 41 中期簡明綜合損益及其他全面收益表 43 中期簡明綜合財務狀況表 45 中期簡明綜合權益變動表 47 中期簡明綜合現金流量表 49 中期簡明綜合財務資料附註 釋義 | --- | --- | --- | |---------- ...

（於開曼群島註冊成立的有限公司） 股份代號；9960 2021 年度報告 Business Review and Outlook 目錄 2 釋義 7 公司資料 9 四年財務概要 10 主席報告 13 業務回顧及展望 17 管理層討論及分析 39 董事及高級管理層 46 企業管治報告 60 環境、社會及管治報告 113 董事會報告 144 獨立核數師報告 148 綜合損益及其他全面收益表 150 綜合財務狀況表 152 綜合權益變動表 154 綜合現金流量表 156 財務報表附註 2021 Annual Report1 釋義 | --- | --- | --- | |--------------------------|-------|---------------------------------------------------------------------------------------------------------------------------| | | | | | 「股東週年大會」 | 指 | 本公司於 2022 年 6 月 1 日（星期三）舉行的股東週年大會 | | 「組織 ...

股份代號：9960 Stock Code: 9960 2021 Interim Report (Incorporated in the Cayman Islands with limited liability) ( 於開曼群島註冊成立的有限公司 )中期 中期報告 2021 2021 Interim Report 目錄 2 4 6 15 28 38 獨立審閱報告 39 中期簡明綜合損益及其他全面收益表 41 中期簡明綜合財務狀況表 43 中期簡明綜合權益變動表 45 中期簡明綜合現金流量表 47 中期簡明綜合財務資料附註 | --- | --- | |------------------|-------| | | | | 釋義 | | | 公司資料 | | | 業務回顧及展望 | | | 管理層討論及分析 | | | | | 其他資料 釋義 | --- | --- | --- | |----------------------|-------|-------------------------------------------------------------------------------| | | ...